AIGH Capital Management’s Aprea Therapeutics APRE Stock Holding History

AIGH Capital Management’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$775K	Buy	1,015,541 +645,000	+174%	+$507K	0.11%	40
2025 Q4	$316K	Sell	370,541 -168,759	-31%	-$207K	0.08%	34
2025 Q3	$795K	Hold	539,300	–	–	0.22%	37
2025 Q2	$913K	Hold	539,300	–	–	0.41%	28
2025 Q1	$1.1M	Hold	539,300	–	–	0.46%	35
2024 Q4	$1.77M	Hold	539,300	–	–	0.55%	28
2024 Q3	$1.48M	Hold	539,300	–	–	0.42%	30
2024 Q2	$2.19M	Hold	539,300	–	–	0.68%	24
2024 Q1	$3.5M	Buy	539,300 +190,000	+54%	+$1.18M	1.05%	27
2023 Q4	$1.64M	Hold	349,300	–	–	0.65%	32
2023 Q3	$1.46M	Hold	349,300	–	–	0.69%	35
2023 Q2	$1.1M	Buy	349,300 +4,300	+1%	+$16K	0.45%	39
2023 Q1	$1.53M	Buy	+345,000	New	+$2.55M	0.56%	37

Other funds holding APRE

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

AIGH Capital Management's APRE Position: Q1 2026 in Review

AIGH Capital Management increased its Aprea Therapeutics (APRE) stake by 174% in Q1 2026, buying an estimated $507K and bringing the position to 1,015,541 shares worth $775K. The position accounts for 0.11% of the portfolio, ranked #40.

AIGH Capital Management first reported a position in APRE in Q1 2023 and has held it in 13 quarters since. The position peaked at $3.5M in Q1 2024. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

AIGH Capital Management held 1,015,541 shares of Aprea Therapeutics worth $775K as of Q1 2026.
AIGH Capital Management bought 645,000 Aprea Therapeutics shares in Q1 2026, an estimated $507K.
Aprea Therapeutics made up 0.11% of AIGH Capital Management's portfolio in Q1 2026, its #40 holding.
AIGH Capital Management first reported a position in Aprea Therapeutics in Q1 2023 and has held it in 13 quarters since.
AIGH Capital Management's Aprea Therapeutics position peaked at $3.5M in Q1 2024.
22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on AIGH Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.